<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02716662</url>
  </required_header>
  <id_info>
    <org_study_id>1307014081</org_study_id>
    <nct_id>NCT02716662</nct_id>
  </id_info>
  <brief_title>Safety of Caprylic Triglycerides in ALS: A Pilot Study</brief_title>
  <official_title>Safety of Caprylic Triglycerides in ALS: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if AC-1204 is safe and tolerated in subjects with&#xD;
      ALS. The reason why the investigator wants to use AC-1204 in patients with ALS is to&#xD;
      determine if, by taking AC-1204, the body will make substances called ketone bodies. Further,&#xD;
      if AC-1204 is well tolerated, the investigators want to change the amount the participant&#xD;
      takes, to determine if the amount of ketone bodies in the blood increase in accordance with&#xD;
      increases in the amount of AC-1204 the participant takes. The investigators want to do this&#xD;
      study because when the investigators gave AC-1204 to mice with ALS, findings suggest the&#xD;
      disease course is altered for the better and that the cause of this change is due to the&#xD;
      presence of ketones in the blood. If AC-1204 can be proven to be safe and able to cause&#xD;
      ketones to increase in the blood, the investigators will likely do subsequent studies to&#xD;
      determine if the presence of ketone bodies will slow or stop the progression of the disease.&#xD;
      However, this study is not designed to determine if AC-1204 will stop or slow the progression&#xD;
      of ALS. It is designed to only determine if patients with ALS can tolerate AC-1204, if ketone&#xD;
      bodies are produced and if the amount of ketone bodies produced increases with increasing&#xD;
      dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Actual">April 25, 2018</completion_date>
  <primary_completion_date type="Actual">May 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ketone levels</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>ALS</condition>
  <arm_group>
    <arm_group_label>Open Label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Axona</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Axona</intervention_name>
    <description>medical powder, supplement food</description>
    <arm_group_label>Open Label</arm_group_label>
    <other_name>AC1204</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Familial or sporadic ALS diagnosed as probable, laboratory-supported probable or&#xD;
             definite according to the World Federation of Neurology El Escorial criteria,&#xD;
&#xD;
          -  Age 18 or older,&#xD;
&#xD;
          -  Capable of providing informed consent and complying with trial procedures,&#xD;
&#xD;
          -  Appel ALS score less than 100,&#xD;
&#xD;
          -  Able to stand on a scale with assistance,&#xD;
&#xD;
          -  Willing to chart food intake during the 12 week study,&#xD;
&#xD;
          -  Patients either not taking Riluzole (Rilutek) or on a stable dose for 30 days or more,&#xD;
&#xD;
          -  Not taking Coenzyme Q10 or on a stable dose and brand for 30 days,&#xD;
&#xD;
          -  Absence of exclusion criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Forced vital capacity &lt;40% of predicted,&#xD;
&#xD;
          -  Dependence on mechanical ventilation for more than 12 hours per day,&#xD;
&#xD;
          -  Exposure to any experimental agent within 30 days of entry or at any time during the&#xD;
             trial,&#xD;
&#xD;
          -  Women who are breastfeeding, who are pregnant or are planning to become pregnant,&#xD;
&#xD;
          -  Women of childbearing potential not practicing a medically accepted form of&#xD;
             contraception,&#xD;
&#xD;
          -  Enrollment in another research study within 30 days of or during this trial,&#xD;
&#xD;
          -  Mini-Mental State Exam (MMSE) score &lt;20,&#xD;
&#xD;
          -  Patients with symptomatic cardiac disease or hypercholesterolemia,&#xD;
&#xD;
          -  Patients with myocardial infarction within 6 months of this trial,&#xD;
&#xD;
          -  Renal dysfunction defined as BUN and creatinine &gt;2xULN,&#xD;
&#xD;
          -  Known mitochondrial disease,&#xD;
&#xD;
          -  BMI&lt;18.5,&#xD;
&#xD;
          -  Prior use of a 4:1 ketogenic diet or Atkins diet within 1 month of this trial,&#xD;
&#xD;
          -  Impaired liver function, defined as AST or ALT of 3xULN,&#xD;
&#xD;
          -  Patients who have a pacemaker or other internal electronic medical device,&#xD;
&#xD;
          -  Known allergy or hypersensitivity to milk or soy products.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>January 6, 2016</study_first_submitted>
  <study_first_submitted_qc>March 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2016</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Weill Medical College of Cornell University</investigator_affiliation>
    <investigator_full_name>Dr. Dale J. Lange</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

